Our findings demonstrate significant associations between LRRN1 expression and the efficacy of several TKIs that are potentially used in breast cancer therapy such as Lapatinib, Bortezomib, Axitinib, and Afatinib (Figures 6P-S). This evidence concerns the gene LRRN1 and breast carcinoma.